Continuous-infusion 5-fluorouracil and cisplatin for advanced/recurrent transitional cell cancer of the bladder: A Southwest Oncology Group trial

Julie A. Kish*, Michael K. Wolf, Paul F. Schellhammer, Maha H A Hussain, Albert B. Einstein, E. David Crawford

*Corresponding author for this work

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Significant toxicities result from the use of MVAC (methotrexate, vinblastine, adriamycin, cisplatin) for advanced/recurrent transitional cell carcinoma of the bladder (ARTCCB). An alternative regimen of 5-fluorouracil (5-FU) and cisplatin was evaluated by Southwest Oncology Group (SWOG). Thirty-eight patients with ARTCCB were treated with continuous infusion 5-FU 1,000 mg/m2/days 1-5 and cisplatin 100 mg/day 1, on a every-21-days schedule. There were two complete responses (CR) and eight partial responses (PR) among 36 eligible patients, for an overall response rate of 28% [95% confidence interval (CI) 14-45%]. Median duration of response was 6 months, and median duration of survival was 9 months. No toxic deaths occurred. Grade 4 leukopenia occurred in 5 patients. Other toxicities were mild. Only two documented infections occurred in 5 patients with neutropenia. The response rate of 28% is better than that achieved with cisplatin alone and not dissimilar to the range of response for MVAC. Toxicities were less and tolerable. This regimen will need further evaluation.

Original languageEnglish (US)
Pages (from-to)327-330
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume20
Issue number4
DOIs
StatePublished - Aug 1997

Keywords

  • 5-Fluorouracil
  • Advanced/recurrent bladder carcinoma
  • Cisplatin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Continuous-infusion 5-fluorouracil and cisplatin for advanced/recurrent transitional cell cancer of the bladder: A Southwest Oncology Group trial'. Together they form a unique fingerprint.

Cite this